で公開中です！詳しく見る

CEL-SCI Corp

CVM

時価総額 $3148万

1.79 USD

+0.05

2.87%

終値時点更新済み 10月16日 16:00 EDT

1日

2.87%

5日間

-8.21%

1か月

20.95%

3か月

55.65%

6か月

-61.42%

年初来

-65.24%

1年

-81.35%

5年間

-99.43%

10年間

-98.94%

概要： CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

従業員数： 44

ヘルスケア医薬品メーカー（総合）

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

ニュートラル

CEL-SCI Reports Fiscal Third Quarter 2026 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.

CEL-SCI Reports Fiscal Third Quarter 2026 Results

ニュートラル

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

ニュートラル

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

ニュートラル

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

ニュートラル

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

ニュートラル

CEL-SCI Announces Closing of Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.

CEL-SCI Announces Closing of Offering

ニュートラル

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

ニュートラル

CEL-SCI Corporation Announces Pricing of Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.

CEL-SCI Corporation Announces Pricing of Offering

ニュートラル

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています